AURUM Biosciences Ltd develops novel pharmaceuticals for use in a number of different clinical indications of high unmet medical need. Aurum has recently completed the preclinical development of ABL-101, its lead stroke management product, and has funding in place to commence phase 2 acute ischaemic stroke studies in 2018. Aurum is seeking strategic partners/investors to expand its development programme. Pipeline includes products for heart disease, cancer, epilepsy, and dementia. Aurum’s lead project utilises an oxygen carrier and proprietary software for use with MRI in Acute Ischaemic Stroke providing a unique combined therapy and diagnostic.